Geovax Labs Inc (GOVX) 0.0800 $GOVX
GeoVax Reports 2016 Second Quarter Financial Results and Provides Corporate Update
Marketwired - Fri Aug 05, 8:00AM CDT
Ongoing Vaccine Programs in Zika, HIV, Hemorrhagic Fevers, Hepatitis B and Cancer
GeoVax Awarded NIH Contract for up to $7.8 Million to Manufacture HIV Vaccine for Advanced Human Clinical Trials
Marketwired - Tue Aug 02, 9:09AM CDT
Supports Production of the DNA Component of GeoVax's GOVX-B11 Preventive HIV Vaccine
GeoVax Discusses Zika Vaccine Development at American Society for Virology's 35th Annual Meeting
Marketwired - Tue Jun 21, 1:30PM CDT
ATLANTA, GA--(Marketwired - Jun 21, 2016) - GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company specializing in the development of human vaccines, announced today that its Chief Scientific Officer, Dr. Harriet Robinson, gave an oral presentation at the American Society for Virology's 35th Annual Meeting, held at Virginia Polytechnic Institute and State University in Blacksburg, Virginia on June 18-22, 2016.
GeoVax to Discuss Zika Vaccine Development Progress at American Society for Virology Meeting
Marketwire Canada - Mon Jun 13, 8:00AM CDT
ATLANTA, GA--(Marketwired - Jun 13, 2016) - GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company specializing in developing human vaccines, announced today that its Chief Scientific Officer, Dr. Harriet Robinson, will give an oral presentation at the American Society for Virology's 35th Annual Meeting, to be held at Virginia Polytechnic Institute and State University in Blacksburg, Virginia on June 18-22, 2016.
GeoVax Developing Vaccine to Treat Chronic Hepatitis B Infection
Marketwired - Mon Jun 06, 8:00AM CDT
Expansion of Company's Pipeline of MVA-VLP Vaccines
GeoVax Ebola Vaccine Protects Non-Human Primates Against Lethal Challenge
Marketwire Canada - Wed Jun 01, 8:00AM CDT
Single Dose Provided 100% Protection, Tetravalent Hemorrhagic Fever Virus Vaccine Under Development
GeoVax Observes HIV Vaccine Awareness Day and Prepares for Next Human Clinical Trial of GOVX-B11
Marketwired - Wed May 18, 8:00AM CDT
Recognizing the Support of the National Institutes of Health and the HIV Vaccine Trials Network in Advancing GeoVax's HIV Vaccine Development Efforts
GeoVax Labs, Inc. Issues Letter to Shareholders
Marketwire Canada - Mon May 09, 8:00AM CDT
Updates on Zika, Ebola and HIV Vaccine Programs and Cancer Immunotherapy Initiative
GeoVax Reports 2016 First Quarter Financial Results
Marketwired - Wed May 04, 8:00AM CDT
ATLANTA, GA--(Marketwired - May 4, 2016) - GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing human vaccines, today announced its financial results for the three months ended March 31, 2016.
GeoVax Presents at Zika Virus Scientific Conference
Marketwired - Mon May 02, 11:00AM CDT
GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company specializing in developing human vaccines, presented today at the conference Bridging the Sciences: Zika Virus, held at the Emory Conference Center in Atlanta, Georgia.
GeoVax Provides Update on Zika Vaccine Program
Marketwired - Mon Apr 18, 8:00AM CDT
GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing human vaccines, provided an update today on its program to develop a safe and effective vaccine to prevent Zika virus infection in humans. No approved vaccine currently exists for this rapidly spreading mosquito-borne disease.
GeoVax Awarded $1.4M NIH Grant
Marketwired - Thu Apr 14, 8:00AM CDT
GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing innovative human vaccines, announced today it has received a Notice of Award from the U.S. National Institutes of Health for a Phase II Small Business Innovative Research (SBIR) grant in support of its clade B HIV vaccine development program for the Americas. The grant award of $740,456 will fund the first year of a two-year project period with a total budget of $1,398,615. The grant, entitled "Enhancing Protective Antibody Responses for a DNA/MVA HIV Vaccine", will support preclinical studies testing the ability of a bivalent (two component) protein boost to enhance the efficacy of the GeoVax Clade B HIV vaccine (GOVX-B11).
GeoVax Reports 2016 Second Quarter Financial Results and Provides Corporate Update
Marketwired - Fri Aug 05, 8:00AM CDT
Ongoing Vaccine Programs in Zika, HIV, Hemorrhagic Fevers, Hepatitis B and Cancer
GeoVax Awarded NIH Contract for up to $7.8 Million to Manufacture HIV Vaccine for Advanced Human Clinical Trials
Marketwired - Tue Aug 02, 9:09AM CDT
Supports Production of the DNA Component of GeoVax's GOVX-B11 Preventive HIV Vaccine
GeoVax Discusses Zika Vaccine Development at American Society for Virology's 35th Annual Meeting
Marketwired - Tue Jun 21, 1:30PM CDT
ATLANTA, GA--(Marketwired - Jun 21, 2016) - GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company specializing in the development of human vaccines, announced today that its Chief Scientific Officer, Dr. Harriet Robinson, gave an oral presentation at the American Society for Virology's 35th Annual Meeting, held at Virginia Polytechnic Institute and State University in Blacksburg, Virginia on June 18-22, 2016.
GeoVax to Discuss Zika Vaccine Development Progress at American Society for Virology Meeting
Marketwire Canada - Mon Jun 13, 8:00AM CDT
ATLANTA, GA--(Marketwired - Jun 13, 2016) - GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company specializing in developing human vaccines, announced today that its Chief Scientific Officer, Dr. Harriet Robinson, will give an oral presentation at the American Society for Virology's 35th Annual Meeting, to be held at Virginia Polytechnic Institute and State University in Blacksburg, Virginia on June 18-22, 2016.
GeoVax Developing Vaccine to Treat Chronic Hepatitis B Infection
Marketwired - Mon Jun 06, 8:00AM CDT
Expansion of Company's Pipeline of MVA-VLP Vaccines
GeoVax Ebola Vaccine Protects Non-Human Primates Against Lethal Challenge
Marketwire Canada - Wed Jun 01, 8:00AM CDT
Single Dose Provided 100% Protection, Tetravalent Hemorrhagic Fever Virus Vaccine Under Development
GeoVax Observes HIV Vaccine Awareness Day and Prepares for Next Human Clinical Trial of GOVX-B11
Marketwired - Wed May 18, 8:00AM CDT
Recognizing the Support of the National Institutes of Health and the HIV Vaccine Trials Network in Advancing GeoVax's HIV Vaccine Development Efforts
GeoVax Labs, Inc. Issues Letter to Shareholders
Marketwire Canada - Mon May 09, 8:00AM CDT
Updates on Zika, Ebola and HIV Vaccine Programs and Cancer Immunotherapy Initiative
GeoVax Reports 2016 First Quarter Financial Results
Marketwired - Wed May 04, 8:00AM CDT
ATLANTA, GA--(Marketwired - May 4, 2016) - GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing human vaccines, today announced its financial results for the three months ended March 31, 2016.
GeoVax Presents at Zika Virus Scientific Conference
Marketwired - Mon May 02, 11:00AM CDT
GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company specializing in developing human vaccines, presented today at the conference Bridging the Sciences: Zika Virus, held at the Emory Conference Center in Atlanta, Georgia.
GeoVax Provides Update on Zika Vaccine Program
Marketwired - Mon Apr 18, 8:00AM CDT
GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing human vaccines, provided an update today on its program to develop a safe and effective vaccine to prevent Zika virus infection in humans. No approved vaccine currently exists for this rapidly spreading mosquito-borne disease.
GeoVax Awarded $1.4M NIH Grant
Marketwired - Thu Apr 14, 8:00AM CDT
GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing innovative human vaccines, announced today it has received a Notice of Award from the U.S. National Institutes of Health for a Phase II Small Business Innovative Research (SBIR) grant in support of its clade B HIV vaccine development program for the Americas. The grant award of $740,456 will fund the first year of a two-year project period with a total budget of $1,398,615. The grant, entitled "Enhancing Protective Antibody Responses for a DNA/MVA HIV Vaccine", will support preclinical studies testing the ability of a bivalent (two component) protein boost to enhance the efficacy of the GeoVax Clade B HIV vaccine (GOVX-B11).
